## Progress towards achieving European Vaccine Action Plan goals, 2017

<table>
<thead>
<tr>
<th>Goal</th>
<th>Indicator</th>
<th>Status</th>
<th>Goal</th>
<th>Indicator</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sustain polio-free status&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Yes (Intermediate)</td>
<td>Meets vaccination coverage targets</td>
<td>DTP3 national immunization coverage ≥95%&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Measles elimination status&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Eliminated</td>
<td>Make evidence-based decisions about introduction of new vaccines&lt;sup&gt;e&lt;/sup&gt;</td>
<td>NITAG made a recommendation about PCV</td>
<td>No</td>
<td>NN</td>
</tr>
<tr>
<td>Rubella elimination status&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Eliminated</td>
<td>NITAG made a recommendation about RV</td>
<td>NITAG made a recommendation about HPV</td>
<td>NN</td>
<td>NN</td>
</tr>
<tr>
<td>Control hepatitis B infection&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Validation pending</td>
<td>Achieve financial sustainability of the national immunization programme&lt;sup&gt;**c&lt;/sup&gt;</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>New vaccines introduced or not introduced based on NITAG evidence-based recommendations  
<sup>b</sup>Country self-sufficient for procuring routine vaccines

### Demographic, income and health expenditure summary, 2017

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population&lt;sup&gt;f&lt;/sup&gt;</td>
<td>9 721 559</td>
</tr>
<tr>
<td>Live births</td>
<td>87 307</td>
</tr>
<tr>
<td>Surviving infants</td>
<td>86 935</td>
</tr>
<tr>
<td>&lt;5 years</td>
<td>432 621</td>
</tr>
<tr>
<td>&lt;15 years</td>
<td>1 391 833</td>
</tr>
<tr>
<td>Neonatal mortality rate (per 1000 live births)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>2.4</td>
</tr>
<tr>
<td>Infant mortality rate (per 1000 live births)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>3.8</td>
</tr>
<tr>
<td>Number of districts&lt;sup&gt;e&lt;/sup&gt;</td>
<td>80</td>
</tr>
<tr>
<td>GNI (per capita, in USD)&lt;sup&gt;g&lt;/sup&gt;</td>
<td>12 920</td>
</tr>
<tr>
<td>Health spending as % of total government expenditure&lt;sup&gt;g&lt;/sup&gt;</td>
<td>10</td>
</tr>
</tbody>
</table>

### Immunization schedule, 2017<sup>e</sup>

<table>
<thead>
<tr>
<th>Age</th>
<th>Vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth</td>
<td>BCG</td>
</tr>
<tr>
<td>2M</td>
<td>DTaPHibIPV, PCV</td>
</tr>
<tr>
<td>3M</td>
<td>DTaPHibIPV</td>
</tr>
<tr>
<td>4M</td>
<td>DTaPHibIPV, PCV</td>
</tr>
<tr>
<td>12M</td>
<td>PCV</td>
</tr>
<tr>
<td>15M</td>
<td>MMR</td>
</tr>
<tr>
<td>18M</td>
<td>DTaPHibIPV</td>
</tr>
<tr>
<td>6Y</td>
<td>DTaPIPv</td>
</tr>
<tr>
<td>11Y</td>
<td>MMR, Tdap</td>
</tr>
<tr>
<td>12Y</td>
<td>HepB_Adult, HPV(2x)</td>
</tr>
</tbody>
</table>
Routine immunization profile

Hungary

### Vaccine coverage estimates, 2013-2017

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
</tr>
<tr>
<td>HepB-BD</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>DTP1</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
</tr>
<tr>
<td>DTP3</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
</tr>
<tr>
<td>HepB3</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Hib3</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
</tr>
<tr>
<td>Pol3</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
</tr>
<tr>
<td>PCV3</td>
<td>92</td>
<td>93</td>
<td>91</td>
<td>98</td>
<td>99</td>
</tr>
<tr>
<td>Rotac</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>RCV1</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>MCV1</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
</tr>
<tr>
<td>MCV2</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
<td>99</td>
</tr>
</tbody>
</table>

### Number of reported cases of vaccine-preventable diseases, 2013-2017

<table>
<thead>
<tr>
<th>Disease</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measles</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>36</td>
</tr>
<tr>
<td>Mumps</td>
<td>8</td>
<td>2</td>
<td>6</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Rubella</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Congenital rubella syndrome</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diphtheria</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tetanus</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Pertussis</td>
<td>20</td>
<td>20</td>
<td>6</td>
<td>5</td>
<td>15</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>1132</td>
<td>1556</td>
<td>979</td>
<td>699</td>
<td>367</td>
</tr>
<tr>
<td>Varicella</td>
<td>34598</td>
<td>28882</td>
<td>41620</td>
<td>37843</td>
<td>33381</td>
</tr>
</tbody>
</table>

### Surveillance with laboratory confirmation of cases, 2017

- **Measles**: Yes
- **Rubella**: Yes
- **Congenital rubella syndrome**: Yes
- **Rotavirus**: No
- **Invasive meningococcal disease**: No
- **Invasive pneumococcal disease**: Yes
- **Invasive Haemophilus influenzae disease**: No

Note: Case-based surveillance (with laboratory confirmation of cases) assessed for measles, rubella, and congenital rubella syndrome. Hospital-based sentinel surveillance and/or population-based surveillance (both with laboratory confirmation of cases) assessed for rotavirus, invasive meningococcal disease, invasive pneumococcal disease, and invasive Haemophilus influenzae disease.
Routine immunization profile
Hungary

Number of reported measles, mumps and rubella cases and MCV coverage estimates, 2013-2017

Number of reported diphtheria, tetanus and pertussis cases and DTP3 coverage estimates, 2013-2017

Reported target population, reported number of DTP3 doses administered and DTP3 reported coverage, 2013-2017

Percentage of districts by DTP3 reported coverage, 2013-2017

DTP1-DTP3 dropout rate, 2013-2017

Immunization system characteristics, 2017

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sustained access to WHO accredited polio, measles, and rubella laboratories</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NITAG in place that meets six WHO criteria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National system in place to monitor AEFI</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Communication plan in place to respond to vaccine safety-related events</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Vaccine hesitancy assessment performed within last 5 years</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Mandatory proof of immunization at school entry</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>

Note: The six WHO NITAG criteria are: 1. legislative or administrative basis for the advisory group; 2. formal written terms of reference; 3. at least five different areas of expertise represented among core members; 4. at least one meeting per year; 5. circulation of the agenda and background documents at least one week prior to meetings; 6. mandatory disclosure of any conflict of interest.
### Routine immunization profile

#### Hungary

**Vaccine stockouts by administrative level**, 2013-2017

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>ND</td>
<td>No</td>
<td>Both</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>DTP</td>
<td>ND</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Both</td>
</tr>
<tr>
<td>HepB</td>
<td>ND</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Both</td>
</tr>
<tr>
<td>Hib</td>
<td>ND</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Pneumo</td>
<td>ND</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Rota</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>OPV</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>IPV</td>
<td>ND</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Measles</td>
<td>ND</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>HPV</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>TT</td>
<td>ND</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>ND</td>
</tr>
</tbody>
</table>

*Data on HPV stockouts have only been collected in JRF since 2016*

### Abbreviations

- AEFI: Adverse event following immunization
- BCG: Bacille Calmette-Guerin vaccine for tuberculosis
- CRS: congenital Rubella Syndrome
- DT: diphtheria-tetanus-containing vaccine
- DTP: diphtheria-tetanus-pertussis-containing vaccine
- DTP1: diphtheria-tetanus-pertussis-containing vaccine, first dose
- DTP3: diphtheria-tetanus-pertussis-containing vaccine, third dose
- GNI: Gross national income
- HepB: hepatitis B
- HepB3: hepatitis B vaccine, third dose
- HepB-BD: hepatitis B vaccine, birth dose
- Hib: Haemophilus influenzae type b
- Hib3: Haemophilus influenzae type b vaccine, third dose
- HPV: human papillomavirus
- IPV: inactivated polio vaccine
- MCV: measles-containing vaccine
- OPV: oral polio vaccine
- PCV: pneumococcal conjugate vaccine
- Pol3: polio-containing vaccine, third dose
- RCV1: rubella-containing vaccine, first dose
- Rotac: rotavirus vaccine-complete series
- TD: tetanus-diphtheria-containing vaccine
- TT: tetanus toxoid vaccine
- W,M,Y: Weeks, Months, Years

### Data sources

- a. European Regional Commission for Certification of Poliomyelitis eradication (RCC) meeting report: www.euro.who.int/32ndRCC
- b. European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thRVC
- e. WHO/UNICEF Joint Reporting Form on immunization (JRF)
- g. World Bank, World Development Indicators
- h. Polio Laboratory Network: www.euro.who.int/poliolabnetwork & Personal communication based on annual accreditation process of the European Measles and Rubella Laboratory Network
- i. Communication with the country

### Map disclaimer

©World Health Organization 2019